Every 8-K that STIMCELL ENERGETICS INC (STME) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow STME and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full STME filings page.
StimCell Energetics Inc. (STME) entered into an Advisory Services Agreement with Stonegate Capital Markets, Inc., under which Stonegate will act as a non-exclusive advisor to identify and introduce potential investors and strategic counterparties for transactions involving StimCell’s assets or new debt and equity securities, on a best-efforts basis and subject to company approval.
Stonegate’s services include quarterly updated research, ongoing investor relations consultation, and coordination of targeted institutional investor meetings. StimCell will pay a success-based advisory fee calculated as a percentage of Gross Proceeds from any qualifying transaction, payable upon closing. The Agreement has an initial three-month term and may be terminated thereafter by either party on 30 days’ written notice. Any related securities offerings are expected to be structured under Rule 506(c) of Regulation D, with StimCell responsible for Form D and applicable state blue-sky filings.
StimCell Energetics Inc. entered into an Advisory Services Agreement with Stonegate Capital Partners to provide research coverage and institutional investor outreach. In return for a twelve-month initial term of services, the company agreed to issue 250,000 shares of common stock to Stonegate.
On March 19, 2026, StimCell issued these 250,000 shares as unregistered securities under Rule 506(b) of Regulation D to an accredited investor. A related news release explains that Stonegate will provide quarterly research, investor relations consulting, and targeted institutional investor meetings to help expand awareness of StimCell’s eBalance® technology and broader wellness and longevity platform.
StimCell Energetics Inc. reported that it has signed a service agreement with the St. Boniface Hospital Albrechtsen Research Centre. The collaboration will explore how the company’s proprietary eBalance® device affects mitochondrial function in cultured sensory neurons, aiming to further define the physiological action of the microcurrents generated by the device.
The update was shared through an informational news release furnished under a Regulation FD disclosure, meaning it is provided for information purposes and is not treated as a formally filed financial statement.